Active Filter(s):
Details:
Burke will market the fixed-dose combination drug, Consensi to lower blood pressure, and celecoxib for the management of the signs and symptoms of osteoarthritis.
Lead Product(s): Amlodipine Besylate,Celecoxib
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IV Product Type: Small molecule
Partner/Sponsor/Collaborator: Coeptis Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 11, 2020